Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2023 Filed Feb 3, 2023 21:39 UTC |
Biller JonathanEVP and Chief Legal Officer
|
GrantCommon Stock | 6,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006913 · doc4.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,587 F1 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2024. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:44 UTC |
Bozic CarmenEVP and CMO
|
GrantCommon Stock | 7,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006934 · doc4.xml · nonDerivative · entry 3 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,964 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2024. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:44 UTC |
Bozic CarmenEVP and CMO
|
GrantCommon Stock | 10,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006934 · doc4.xml · nonDerivative · entry 2 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,098 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:44 UTC |
Bozic CarmenEVP and CMO
|
GrantCommon Stock | 10,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006934 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,836 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:48 UTC |
Kewalramani ReshmaDirector · CEO & President
|
GrantCommon Stock | 26,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006946 · doc4.xml · nonDerivative · entry 3 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,076 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2024. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:48 UTC |
Kewalramani ReshmaDirector · CEO & President
|
GrantCommon Stock | 29,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006946 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,104 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:48 UTC |
Kewalramani ReshmaDirector · CEO & President
|
GrantCommon Stock | 12,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006946 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,986 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:53 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
GrantCommon Stock | 10,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006958 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,001 F3 · shares: Restricted stock unit award that fully vested upon grant. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:53 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
GrantCommon Stock | 34,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006958 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,775 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/24/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:53 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
GrantCommon Stock | 31,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006958 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,885 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:56 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
GrantCommon Stock | 7,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006973 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,752 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2024. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:56 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
GrantCommon Stock | 8,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006973 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,886 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:56 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
GrantCommon Stock | 10,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006973 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,676 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:58 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
GrantCommon Stock | 7,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006980 · doc4.xml · nonDerivative · entry 3 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,270 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2024. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:58 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
GrantCommon Stock | 12,314 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006980 · doc4.xml · nonDerivative · entry 2 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,404 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:58 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
GrantCommon Stock | 9,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006980 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,090 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 03/01/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:01 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
GrantCommon Stock | 7,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006996 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,412 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2024. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:01 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
GrantCommon Stock | 10,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006996 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,546 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:01 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
GrantCommon Stock | 6,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006996 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,284 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:03 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
GrantCommon Stock | 9,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007012 · doc4.xml · nonDerivative · entry 3 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,890 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2024. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:03 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
GrantCommon Stock | 10,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007012 · doc4.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,450 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:03 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
GrantCommon Stock | 10,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007012 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,188 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:14 UTC |
SACHS BRUCE IDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,200 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-23-006204 · doc4.xml · derivative · entry 3 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,300 Underlying: Common Stock · 1,200 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:14 UTC |
SACHS BRUCE IDirector
|
SaleCommon Stock | 1,200 | $325.01 | $390,012.00 |
DisclosureSEC source: 0001209191-23-006204 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,210 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $325.01 (range $325.00 to $325.01). Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:14 UTC |
SACHS BRUCE IDirector
|
Exercise / conversionCommon Stock | 1,200 | $72.14 | $86,568.00 |
DisclosureSEC source: 0001209191-23-006204 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:18 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 106 | $325.00 | $34,450.00 |
DisclosureSEC source: 0001209191-23-006215 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,998 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 21:45 UTC |
CARNEY LLOYDDirector
|
SaleCommon Stock | 324 | $321.84 | $104,276.16 |
DisclosureSEC source: 0001209191-23-005717 · doc4.xml · nonDerivative · entry 3 CARNEY LLOYD · CIK 0001204424 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,150 F1 · kind: Transaction made pursuant to Mr. Carney's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Carney undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $321.84 (range $321.54 to $322.23). Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 21:45 UTC |
CARNEY LLOYDDirector
|
SaleCommon Stock | 1,000 | $320.70 | $320,700.00 |
DisclosureSEC source: 0001209191-23-005717 · doc4.xml · nonDerivative · entry 2 CARNEY LLOYD · CIK 0001204424 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,474 F1 · kind: Transaction made pursuant to Mr. Carney's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Carney undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $320.70 (range $320.43 to $321.31). Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 21:45 UTC |
CARNEY LLOYDDirector
|
SaleCommon Stock | 1,376 | $320.08 | $440,430.08 |
DisclosureSEC source: 0001209191-23-005717 · doc4.xml · nonDerivative · entry 1 CARNEY LLOYD · CIK 0001204424 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,474 F1 · kind: Transaction made pursuant to Mr. Carney's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Carney undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $320.08 (range $319.40 to $320.38). Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 21:42 UTC |
Lee YuchunDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,429 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-23-005712 · doc4.xml · derivative · entry 5 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,429 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 21:42 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 80 | $323.33 | $25,866.40 |
DisclosureSEC source: 0001209191-23-005712 · doc4.xml · nonDerivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 21:42 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 970 | $322.20 | $312,534.00 |
DisclosureSEC source: 0001209191-23-005712 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,955 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $322.20 (range $321.75 to $322.74). Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 21:42 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 379 | $321.31 | $121,776.49 |
DisclosureSEC source: 0001209191-23-005712 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,925 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $321.31 (range $320.62 to $321.59). Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 21:42 UTC |
Lee YuchunDirector
|
Exercise / conversionCommon Stock | 1,429 | $72.14 | $103,088.06 |
DisclosureSEC source: 0001209191-23-005712 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:18 UTC |
Lee YuchunDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · derivative · entry 13 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,429 Underlying: Common Stock · 4,000 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Fully vested. Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:18 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 680 | $320.94 | $218,239.20 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 11 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11 · price: Open market sales reported on this line occurred at a weighted average price of $320.94 (range $320.89 to $320.99). Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:18 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 400 | $320.25 | $128,100.00 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 10 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,555 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $320.25 (range $319.80 to $320.77). Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:18 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 478 | $319.25 | $152,601.50 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 9 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,955 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $319.25 (range $318.79 to $319.56). Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:18 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 1,000 | $317.95 | $317,950.00 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 8 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,433 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $317.95 (range $317.43 to $318.35). Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:18 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 1,140 | $316.82 | $361,174.80 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 7 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,433 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $316.82 (range $316.23 to $317.16). Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:18 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 302 | $315.42 | $95,256.84 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 6 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,573 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $315.42 (range $315.23 to $315.66). Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:18 UTC |
Lee YuchunDirector
|
Exercise / conversionCommon Stock | 4,000 | $72.14 | $288,560.00 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 5 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:13 UTC |
Kewalramani ReshmaDirector · CEO & President
|
SaleCommon Stock | 10,000 | $315.05 | $3,150,500.00 |
DisclosureSEC source: 0001209191-23-005219 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,598 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $315.05 (range $315.00 to $315.23). Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:18 UTC |
Lee YuchunDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · derivative · entry 12 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,429 Underlying: Common Stock · 4,000 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Fully vested. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:18 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 579 | $314.95 | $182,356.05 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $314.95 (range $314.58 to $315.14). Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:18 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 2,621 | $314.10 | $823,256.10 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,454 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $314.10 (range $313.53 to $314.50). Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:18 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 800 | $312.80 | $250,240.00 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,075 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $312.80 (range $312.41 to $313.06). Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:18 UTC |
Lee YuchunDirector
|
Exercise / conversionCommon Stock | 4,000 | $72.14 | $288,560.00 |
DisclosureSEC source: 0001209191-23-005234 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2023 Filed Jan 25, 2023 21:08 UTC |
Lee YuchunDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-23-004816 · doc4.xml · derivative · entry 7 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,429 Underlying: Common Stock · 4,000 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| January 24, 2023 Filed Jan 25, 2023 21:08 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 1,489 | $313.36 | $466,593.04 |
DisclosureSEC source: 0001209191-23-004816 · doc4.xml · nonDerivative · entry 5 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $313.36 (range $313.00 to $313.73). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.